DE3017707A1 - Verfahren und reagens zum nachweis von fibrinmonomer - Google Patents
Verfahren und reagens zum nachweis von fibrinmonomerInfo
- Publication number
- DE3017707A1 DE3017707A1 DE19803017707 DE3017707A DE3017707A1 DE 3017707 A1 DE3017707 A1 DE 3017707A1 DE 19803017707 DE19803017707 DE 19803017707 DE 3017707 A DE3017707 A DE 3017707A DE 3017707 A1 DE3017707 A1 DE 3017707A1
- Authority
- DE
- Germany
- Prior art keywords
- latex
- reagent
- agglutination
- fibrin
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 32
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 9
- 239000000178 monomer Substances 0.000 title claims 2
- 229920000126 latex Polymers 0.000 claims abstract description 26
- 239000004816 latex Substances 0.000 claims abstract description 25
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims abstract description 22
- 238000001514 detection method Methods 0.000 claims abstract description 17
- 230000004520 agglutination Effects 0.000 claims abstract description 13
- 108010073651 fibrinmonomer Proteins 0.000 claims abstract description 13
- 108010073385 Fibrin Proteins 0.000 claims abstract description 9
- 102000009123 Fibrin Human genes 0.000 claims abstract description 9
- 229950003499 fibrin Drugs 0.000 claims abstract description 9
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 8
- 239000013060 biological fluid Substances 0.000 claims abstract description 5
- 239000012530 fluid Substances 0.000 claims abstract 2
- 108010049003 Fibrinogen Proteins 0.000 claims description 23
- 102000008946 Fibrinogen Human genes 0.000 claims description 23
- 229940012952 fibrinogen Drugs 0.000 claims description 23
- 239000002245 particle Substances 0.000 claims description 19
- 108090000190 Thrombin Proteins 0.000 claims description 9
- 229960004072 thrombin Drugs 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 238000011534 incubation Methods 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 239000004793 Polystyrene Substances 0.000 claims description 4
- 229940088598 enzyme Drugs 0.000 claims description 4
- 238000013207 serial dilution Methods 0.000 claims description 3
- 239000008366 buffered solution Substances 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 241000270295 Serpentes Species 0.000 claims 1
- 239000002574 poison Substances 0.000 claims 1
- 231100000614 poison Toxicity 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 6
- 210000002381 plasma Anatomy 0.000 description 19
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 16
- 239000000872 buffer Substances 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 239000000523 sample Substances 0.000 description 13
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000004471 Glycine Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 108010027612 Batroxobin Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 108010039627 Aprotinin Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960004405 aprotinin Drugs 0.000 description 2
- 229960002210 batroxobin Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 230000003311 flocculating effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical group C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000004071 soot Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/75—Fibrin; Fibrinogen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analyzing Materials By The Use Of Magnetic Means (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19803017707 DE3017707A1 (de) | 1980-05-08 | 1980-05-08 | Verfahren und reagens zum nachweis von fibrinmonomer |
| ES501364A ES501364A0 (es) | 1980-05-08 | 1981-04-14 | Procedimiento para la deteccion y determinacion de monomero de fibrina en liquidos biologicos |
| US06/256,212 US4429040A (en) | 1980-05-08 | 1981-04-21 | Method and reagent for the detection of fibrin monomer |
| DD81229722A DD158954A5 (de) | 1980-05-08 | 1981-05-04 | Verfahren und reagenz zum nachweis von fibrinmonomer |
| EP81103395A EP0039885B1 (de) | 1980-05-08 | 1981-05-05 | Verfahren und Reagens zum Nachweis von Fibrinmonomer |
| AT81103395T ATE7542T1 (de) | 1980-05-08 | 1981-05-05 | Verfahren und reagens zum nachweis von fibrinmonomer. |
| DE8181103395T DE3163585D1 (en) | 1980-05-08 | 1981-05-05 | Method and reagent for the detection of fibrin monomer |
| JP6838181A JPS574551A (en) | 1980-05-08 | 1981-05-08 | Method of and reagent for detecting fibrinmonomer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19803017707 DE3017707A1 (de) | 1980-05-08 | 1980-05-08 | Verfahren und reagens zum nachweis von fibrinmonomer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3017707A1 true DE3017707A1 (de) | 1981-11-12 |
Family
ID=6101941
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19803017707 Withdrawn DE3017707A1 (de) | 1980-05-08 | 1980-05-08 | Verfahren und reagens zum nachweis von fibrinmonomer |
| DE8181103395T Expired DE3163585D1 (en) | 1980-05-08 | 1981-05-05 | Method and reagent for the detection of fibrin monomer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE8181103395T Expired DE3163585D1 (en) | 1980-05-08 | 1981-05-05 | Method and reagent for the detection of fibrin monomer |
Country Status (7)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3330699A1 (de) * | 1983-08-25 | 1985-03-07 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur gleichzeitigen bestimmung von fibrinogen und fibrinogen-spaltprodukten im plasma |
| AU4158785A (en) * | 1984-03-26 | 1985-11-01 | International Health Services | A method of determining the clotting time of blood and particulate reagents therefor |
| DE3430906A1 (de) * | 1984-08-22 | 1986-02-27 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur bestimmung von fibrinmonomer in plasma |
| DD261844A1 (de) * | 1986-07-09 | 1988-11-09 | Adw Ddr | Verfahren zur praezipitation von fibrinmonomeren |
| US4921787A (en) * | 1987-05-01 | 1990-05-01 | Cambridge Bioscience Corporation | Detection of antibodies to human immunodeficiency virus by agglutination of antigen coated latex |
| AU644205B2 (en) * | 1990-08-23 | 1993-12-02 | New York Blood Center, Inc., The | Assays using a soluble fibrin-like monomer |
| CN1091315A (zh) * | 1992-10-08 | 1994-08-31 | E·R·斯奎布父子公司 | 血纤维蛋白封闭剂组合物及其使用方法 |
| US5733446A (en) * | 1994-12-02 | 1998-03-31 | Bristol-Myers Squibb Company | Centrifuge with annular filter |
| CN1083284C (zh) * | 1994-12-02 | 2002-04-24 | 布里斯托尔-迈尔斯斯奎布公司 | 从血浆中分离纤维蛋白的方法和设备 |
| US5830352A (en) * | 1994-12-02 | 1998-11-03 | Bristol-Myers Squibb Company | Centrifuge reagent delivery system |
| DE19756773A1 (de) | 1997-12-19 | 1999-06-24 | Dade Behring Marburg Gmbh | Neues Verfahren und Diagnosemittel zur Hämostase-Diagnostik |
| RU2298798C1 (ru) * | 2006-01-17 | 2007-05-10 | Общество с ограниченной ответственностью "Биочип-Аналитика" (ООО "Биочип-Аналитика") | Способ контроля биологической пробы в реакции латекс-агглютинации и аналитическая система для его осуществления |
| CA3153941A1 (en) * | 2019-10-17 | 2021-04-22 | Mary POMEROY | Coagulation assay apparatus and methods thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3088875A (en) | 1959-10-27 | 1963-05-07 | Hyland Lab | Immunological diagnostics utilizing polystyrene latex particles of 0.15 to 0.25 micron |
| GB1362776A (en) * | 1970-07-17 | 1974-08-07 | Wellcome Found | Immunological reagent |
| NL7602422A (nl) * | 1976-03-08 | 1977-09-12 | Leuven Res & Dev Vzw | Trombosetest. |
| US4208185A (en) | 1976-08-16 | 1980-06-17 | Mitsubishi Chemical Industries Limited | Method and apparatus for the measurement of antigens and antibodies |
| US4090846A (en) | 1976-10-20 | 1978-05-23 | Fisher Scientific Company | Indirect latex test for determination of fibrinogen degradation products |
| CA1101330A (en) | 1977-09-19 | 1981-05-19 | Ernst A. Fischer | Immunological material bonded to carboxylated latex polymer and process for making it |
-
1980
- 1980-05-08 DE DE19803017707 patent/DE3017707A1/de not_active Withdrawn
-
1981
- 1981-04-14 ES ES501364A patent/ES501364A0/es active Granted
- 1981-04-21 US US06/256,212 patent/US4429040A/en not_active Expired - Fee Related
- 1981-05-04 DD DD81229722A patent/DD158954A5/de not_active IP Right Cessation
- 1981-05-05 AT AT81103395T patent/ATE7542T1/de not_active IP Right Cessation
- 1981-05-05 DE DE8181103395T patent/DE3163585D1/de not_active Expired
- 1981-05-05 EP EP81103395A patent/EP0039885B1/de not_active Expired
- 1981-05-08 JP JP6838181A patent/JPS574551A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| DD158954A5 (de) | 1983-02-09 |
| JPS574551A (en) | 1982-01-11 |
| EP0039885A1 (de) | 1981-11-18 |
| JPS6360862B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1988-11-25 |
| ES8202639A1 (es) | 1982-02-16 |
| EP0039885B1 (de) | 1984-05-16 |
| US4429040A (en) | 1984-01-31 |
| DE3163585D1 (en) | 1984-06-20 |
| ES501364A0 (es) | 1982-02-16 |
| ATE7542T1 (de) | 1984-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2450523B2 (de) | Verfahren zum immunologischen nachweis von proteinen | |
| EP0019741A1 (de) | Latex-Reagenz, Verfahren zu seiner Herstellung, seine Verwendung und ein das Reagenz enthaltendes Mittel | |
| DE1648999C3 (de) | Verfahren zur immunochemischen Bestimmung von Antigenen und Antikörpern | |
| CH637770A5 (de) | Zur durchfuehrung von immunoassays sowie zur abtrennung eines antikoerper/antigen-komplexes aus einer fluessigkeitsprobe geeignetes reagenz sowie verwendung dieses reagenzes. | |
| EP0039885B1 (de) | Verfahren und Reagens zum Nachweis von Fibrinmonomer | |
| DE2651139C3 (de) | Reagens zur Durchführung eines Direktagglutinationstests zum Schwangerschaftsnachweis und Verfahren zu seiner Herstellung | |
| DD202178A5 (de) | Verfahren und reagens zur untersuchung von antigen-antikoerper-reaktionen | |
| DE2134928A1 (de) | Biologisches Reagens | |
| DE69403961T3 (de) | Verfahren zur bestimmung der von blutplättchen abstammenden mikrovesikel | |
| DE3105555C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE68912477T3 (de) | Verfahren zum messen der biologischen wirkung von antithrombin iii und reagenzkit zu dessen messung | |
| DE3650238T2 (de) | Immunologische Bestimmung eines Gerinnungsfaktors in einer Probe. | |
| DE3430906A1 (de) | Verfahren zur bestimmung von fibrinmonomer in plasma | |
| DE69016858T2 (de) | Verfahren und Reagenziensatz zur Bestimmung der funktionalen Aktivität von Protein S in menschlichem Plasma. | |
| DE69013730T2 (de) | Für ganze Zellen geeigneter Satz und Verfahren zu enzymatischen Bestimmungen. | |
| DE2601372A1 (de) | Verfahren zur quantitativen bestimmung von antithrombin iii | |
| EP0433927A2 (de) | Mittel zur Verbesserung der Wiederfindung von Annexinen | |
| DD204313A5 (de) | Immunochemisches reagens | |
| DE2934756A1 (de) | Zusammensetzung zur bestimmung von beta 2 -humanmikroglobulin und verfahren zu deren herstellung und deren verwendung | |
| DE69332764T2 (de) | Hydroxylamin enthaltendes kontrollreagenz | |
| DE69025008T2 (de) | Verfahren für direkte chemische Bindung des D-Dimers aus einer biologischen Probe zwecks Diagnostik und Überwachung von thrombolytischen und hyperkoagulablen Zuständen | |
| EP0554657B1 (de) | Verfahren zur Bestimmung von Antigenen oder Antikörpern in Gegenwart eines Immunkomplexes | |
| DE2638250C2 (de) | Diagnostisches Verfahren zum Bestimmen der Anwesenheit oder Abwesenheit eines spezifischen Proteins in einer biologischen Probe, sowie Vorrichtung zur Durchführung des Verfahrens | |
| KAI | Factor XIII | |
| EP0253255A2 (de) | Verfahren und Testkit zum Nachweis von Fibrinmonomeren im Blut |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |